Szilard Nemes

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Non-parametric differential methylation analysis characterizes histotype-specific promoter regions in epithelial ovarian cancer.

Non-parametric differential methylation analysis characterizes histotype-specific promoter regions in epithelial ovarian cancer.

Journal: Epigenetics

Published: September 02, 2026

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.

Journal: BMJ open respiratory research

Published: July 04, 2025

First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor.

First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor.

Journal: The Journal of allergy and clinical immunology

Published: June 25, 2025

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.

Journal: British journal of clinical pharmacology

Published: April 01, 2025

Integrative analysis of epigenetic and transcriptional interrelations identifies histotype-specific biomarkers in early-stage ovarian carcinoma.

Integrative analysis of epigenetic and transcriptional interrelations identifies histotype-specific biomarkers in early-stage ovarian carcinoma.

Journal: Journal of ovarian research

Published: March 03, 2025

A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055.

A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055.

Journal: iScience

Published: November 11, 2024

The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial.

The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial.

Journal: British journal of clinical pharmacology

Published: December 07, 2023

AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study.

AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study.

Journal: Clinical and translational science

Published: June 12, 2023

Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis.

Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis.

Journal: BMJ open

Published: December 22, 2022

Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma.

Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma.

Journal: Frontiers in oncology

Published: November 30, 2022

Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators.

Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators.

Journal: Entropy (Basel, Switzerland)

Published: April 04, 2022

Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials.

Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials.

Journal: Respiratory medicine

Published: July 13, 2021

Showing 1-12 of 80

Last Updated: 09/26/2026